证券代码：603233 证券简称：大参林 公告编号：2025-064 大参林医药集团股份有限公司 第四届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 大参林医药集团股份有限公司（以下简称"公司"）第四届董事会第二十八 次会议通知于 2025 年 10 月 20 日发出，于 2025 年 10 月 29 日以通讯方式召开， 本次会议应到董事 8 人，实到董事 8 人。本次会议由董事长柯云峰先生召集并主 持，公司监事及部分高级管理人员列席了会议。本次会议的出席人数、召集、召 开及表决程序均符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律 法规、行政部门规章、规范性文件和《大参林医药集团股份有限公司章程》（以 下简称"《公司章程》"）的规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 根据《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规及《公 司章程》等规章制度，按照中国证券监督管 ...

大参林医药集团股份有限公司 2025 年第三季度报告 证券代码：603233 证券简称：大参林 大参林医药集团股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 6,545,672,910.36 | 2.51 | ...

证券代码：603233 证券简称：大参林 公告编号：2025-072 大参林医药集团股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.34元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/11/5 | － | 2025/11/6 | 2025/11/6 | 差异化分红送转： 是 （1）差异化分红方案 公司分别于 2024 年 3 月 15 日、2024 年 4 月 1 日召开第四届董事会第十三次会议、 2024 年第二次临时股东大会，审议通过了《关于以集中竞价交易方式回购公司股份方案 的议案》，同意公司以集中竞价交易方式回购公司股份，回购的股份全部用于后续实施股 权激励。回购资金总额不低于 1 亿元，不超过 2 亿元，资金来源为公司自有资金。回购期 限自公司 2024 年第二次临时股东大会审议 ...

Core Insights - In 2025, Dazhenglin Pharmaceutical Group achieved a revenue of 13.52 billion yuan, a year-on-year increase of 1.3%, and a net profit of 798 million yuan, up 21.4%, showcasing strong profitability amidst a declining retail pharmacy market [1] Group 1: National Expansion and Scale Effect - As of June 30, 2025, Dazhenglin had a total of 16,833 stores across 21 provinces, with 10,370 direct-operated and 6,463 franchised stores [2] - The company adopted a "self-built + acquisition + direct franchise" strategy, achieving breakthroughs in both existing market penetration and new market coverage [2] - In the East China market, Dazhenglin opened 134 new stores, reaching a total of 943 stores, and improved store efficiency by 18% in large stores and 12% in community stores [2] Group 2: Integration of Pet Economy and Retail Pharmacy - Dazhenglin entered the pet economy market, covering over 3,000 stores nationwide, contributing 12% to revenue [3] - The company established a consumption ecosystem through "drug retail + light medical services + ecological products," achieving a 68% repurchase rate in trial stores [3] - Dazhenglin launched its own pet food brand "CanPet" and set up a 406 million yuan pet industry fund to invest in pet healthcare and smart hardware [3] Group 3: Digitalization and Professional Services - The company implemented over ten digital projects, achieving a 93.54% online-to-offline service coverage and a 2.1 percentage point increase in online business gross margin [4] - Dazhenglin has a team of over 20,000 pharmacy professionals and provides medication therapy management services, serving over 3 million patients [4] - The AI system "AI Xiaosan" improved consultation efficiency, completing 4.7 million professional consultations in the first half of the year [4] Group 4: Social Responsibility and Business Success - In the first half of 2025, Dazhenglin distributed dividends and repurchased shares totaling 3.834 billion yuan, exceeding the total funds raised since its listing [5] - The company implemented recycling initiatives, saving over 21.57 million cardboard boxes, and reduced energy consumption by over 40% [5] - Dazhenglin's social initiatives provided health checks and medication safety education to over 1 million people [5] Group 5: Future Outlook - Dazhenglin aims to expand its market share through an integrated business model and a nationwide logistics network, with plans to invest 1 billion yuan in pet business over the next three years [6][7] - The company plans to establish 5,000 pet-friendly stores by 2028 and explore a "pet insurance + health management" payment model [7] - Dazhenglin is transitioning from regional leader to a global health service leader, driven by innovation and responsibility [7]

Group 1 - The core point of the announcement is that the controlling shareholder, Mr. Ke Jinlong, has released a portion of his pledged shares, specifically 31,680,000 shares, which represents 15.31% of his total holdings and 2.78% of the company's total share capital [1][1][1] Group 2 - The specific details of the share release include the number of shares released and the percentage of total holdings affected [1][1] - The announcement confirms that the release of the pledge has been completed and the registration procedures have been finalized [1]

Group 1 - The core announcement is about the release of part of the pledged shares by the controlling shareholder, Mr. Ke Jinlong, who has released 31,680,000 shares [1][3] - The released shares represent 15.31% of Mr. Ke Jinlong's total holdings and 2.78% of the company's total share capital [3] - The announcement confirms that the company’s board of directors guarantees the truthfulness, accuracy, and completeness of the content [1] Group 2 - The announcement was made on October 28, 2025, following the completion of the pledge release registration procedures [3] - The document includes a reminder that all data in the tables may have rounding differences [1]

Core Points - Dacilin announced on October 27 that it received a notification from its controlling shareholder, Mr. Ke Jinlong, regarding the release of a portion of his pledged shares, totaling 31,680,000 shares [1] Summary by Category Company Actions - Dacilin has completed the registration procedures for the release of the pledged shares [1] Shareholder Information - Mr. Ke Jinlong, a controlling shareholder, is the individual who notified the company about the release of the pledged shares [1]

证券代码：603233 证券简称：大参林 公告编号：2025-063 大参林医药集团股份有限公司 关于控股股东部分股份解除质押的公告 一、本次股份解除质押的具体情况 | | | | | | | | | 已质押股份情况 | 未质押股份情 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其所 | 占公 | | | 况 | 未质 | | | 持股数量 | 持股 | 本次质押前 | 本次质押后 | 持股份 | 司总 | 已质押 | 已质押 | 未质押 | 押股 | | 股东名称 | （股） | 比例 | 累计质押数 | 累计质押数 | 比例 | 股本 | 股份中 | 股份中 | 股份中 | 份中 | | | | (%) | 量（股） | 量（股） | | 比例 | 限售股 | | 限售股 | | | | | | | | （%） | （%） | 份数量 | 冻结股 | 份数量 | 冻结 | | | | | | | | | | 份数量 | | 股份 | | | | | | | | | （股） | | ...

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]

| 证券代码：603233 | 证券简称：大参林 | 公告编号：2025-062 | | --- | --- | --- | | 债券代码：113605 | 债券简称：大参转债 | | 因公司实施 2025 年半年度权益分派,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 113605 | 大参转债 | 可转债转股停牌 | 2025/10/29 | | | | 一、权益分派的基本情况 2025 年 9 月 15 日，公司召开了 2025 年第二次临时股东大会，审议通过了《关 于公司 2025 年半年度利润分配方案的议案》，拟以实施权益分派股权登记日的总 股本扣减回购部分的股份为基数分配利润，向全体股东每股派发现金股利人民币 0.34 元(含税),不送红股，不进行资本公积转增股本。在实施权益分派的股权登记 日前公司总股本发生变动的，拟维持分配比例不变，相应调整分配总额。 本次权益分派实施后，公司将依据《大参林公开发行可转换公司债券 ...